Welcome to our dedicated page for Biofrontera SEC filings (Ticker: BFRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biofrontera Inc. (NASDAQ: BFRI) SEC filings page provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Biofrontera is a U.S.-based biopharmaceutical company focused on dermatology and photodynamic therapy (PDT), commercializing Ameluz® and the RhodoLED® lamp series for actinic keratoses and developing additional indications such as superficial basal cell carcinoma and acne vulgaris.
Through its current and periodic reports, investors can review how Biofrontera describes its business, risk factors and financial condition. Form 8-K filings document material events, including quarterly financial results, strategic transactions with Biofrontera AG to acquire all U.S. rights to Ameluz® and RhodoLED®, private placements of Series C and Series D convertible preferred stock, and the divestiture of the Xepi® antibiotic cream license. Other 8-Ks detail Nasdaq listing compliance notices and stockholder meeting outcomes.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically include information on revenues from dermatology products, operating expenses, liquidity, and discussions of clinical and regulatory progress for Ameluz®-PDT. These filings also outline the company’s reliance on product sales, competition in dermatology, intellectual property matters, and other risks relevant to its PDT-focused business model.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as revenue trends, changes in earnout structures, capital raises, and outcomes of clinical and regulatory milestones. Investors can also use this page to monitor Form 4 insider transaction reports, as well as proxy and registration statements that discuss governance, capital structure and preferred stock offerings.
By combining real-time EDGAR updates with AI-generated insights, this page offers a structured view of Biofrontera’s regulatory history, financial reporting, and material corporate events tied to its dermatology and photodynamic therapy strategy.
Biofrontera Inc. director Kevin Daniel Weber reported receiving an employee stock option grant to acquire 20,000 shares of the company’s stock. The option carries an exercise price of $0.00 per share and represents a new award, bringing his total directly held derivative securities from this grant to 20,000 options.
According to the disclosure, the option vests in twelve equal monthly installments beginning on April 4, 2026, meaning the right to exercise will phase in over one year. The filing notes that other options with different terms are not included in this reported transaction.
Biofrontera Inc. CEO and Chairman Hermann Luebbert reported several equity awards and an option-related share conversion. On March 4, 2026, he received 125,000 restricted stock units and an employee stock option for 125,000 shares, both at a price of $0.00 per unit or option. The restricted stock units vest in two equal yearly installments beginning on March 4, 2027, and may be settled in shares, cash, or a combination within 60 days of each vesting date. The option vests in two equal installments on September 4, 2026 and March 4, 2027. On March 5, 2026, 137,500 restricted stock units were exercised or converted into 137,500 shares of common stock at $0.00 per share, bringing his directly held common stock to 290,211 shares after the transaction.
Biofrontera Inc. Chief Financial Officer Eugene Frederick Leffler reported equity compensation activity, mainly awards and a derivative conversion. On March 4, 2026, he received 62,500 restricted stock units and 62,500 employee stock options, both granted for no cash consideration.
On March 5, 2026, 87,500 restricted stock units were converted into 87,500 shares of common stock at a price of $0.00 per share, leaving him with 175,000 common shares held directly after the transaction.
Lanckriet Heikki reported acquisition or exercise transactions in this Form 4 filing.
Biofrontera Inc. director Heikki Lanckriet received a grant of employee stock options covering 20,000 shares on March 4, 2026. These options were awarded at a stated price of $0.0000 per share and represent a new direct derivative holding of 20,000 options.
The option grant vests in twelve equal monthly installments, beginning on April 4, 2026, spreading the benefit to the director over one year. The disclosure notes that options with different terms are not included in this reported amount.
Hoffman Beth J. reported acquisition or exercise transactions in this Form 4 filing.
Biofrontera Inc. director Beth J. Hoffman reported receiving an award of 20,000 employee stock options on March 4, 2026. The options were granted at a reported price of $0.0000 per share. They vest in twelve equal monthly installments beginning on April 4, 2026. After this grant, she holds 20,000 options directly.
Biofrontera Inc. reported that Chief Commercial Officer George Patrick Jones acquired new equity-based compensation. He received 50,000 restricted stock units, each representing a contingent right to one share of BFRI common stock awarded for no consideration.
He also received an option for 50,000 shares with a grant price of $0.00. The option vests in two equal installments on September 4, 2026 and March 4, 2027. The restricted stock units vest in two equal yearly installments beginning March 4, 2027, and each vested unit will be settled in shares, cash, or a combination within 60 days at the company’s discretion.
Biofrontera Inc. director John J. Borer III received an employee stock option grant on March 4, 2026. The award covers options to purchase 20,000 shares, reported at a price of $0.00 per share as a derivative security grant. According to the terms, the option vests in twelve equal monthly installments beginning on April 4, 2026, so the director earns the right to exercise portions of the option gradually over one year.
Biofrontera Inc. reports a significant development in its patent dispute with Sun Pharmaceutical Industries. On February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision finding all challenged claims of Sun’s U.S. Patent No. 11,697,028 unpatentable.
Sun may still request rehearing, seek review by the Director of the U.S. Patent and Trademark Office, or appeal to the U.S. Court of Appeals for the Federal Circuit, so the outcome is not yet final. The company notes that the impact of this decision on ongoing proceedings in the U.S. District Court for the District of Massachusetts and the International Trade Commission cannot be determined at this time.
Rosalind Master Fund L.P. and related parties report beneficial ownership of approximately 9.9% of Biofrontera Inc. common shares. The stake is reported on a passive basis and is calculated using 11,648,323 common shares outstanding as of November 10, 2025.
Rosalind Master Fund L.P. may be deemed to beneficially own 1,140,764 common shares, with additional 15,048,017 shares issuable from preferred shares and convertible debt that are subject to a 9.99% ownership blocker and therefore not currently exercisable. Rosalind Advisors, Inc. acts as investment adviser, and portfolio managers Steven Salamon and Gilad Aharon may be deemed beneficial owners but disclaim beneficial ownership.
Biofrontera Inc. reported positive, statistically significant Phase 3 results for Ameluz® photodynamic therapy (PDT) to treat mild to moderate actinic keratoses on the extremities, neck, and trunk using its RhodoLED® platform.
Ameluz® PDT achieved complete clearance in 45.6% of patients in the Full Analysis Set, versus 16.7% with vehicle PDT (p < 0.0003), and 53.2% versus 22.2% in the Per Protocol Set (p < 0.001). Lesion clearance reached 73.1% in the Full Analysis Set and 80.3% in the Per Protocol Set. Investigators rated cosmetic outcomes as good or very good in 75.2% of patients, and 86.3% indicated they would choose PDT again. Based on these data, Biofrontera plans to submit a supplemental New Drug Application to the FDA in the third quarter of 2026 for a potential label expansion beyond the face and scalp.